Dopamine d2-receptor density in humans as assessed with spet and the new high-affinity ligand 123i-ncq298 a pilot study

Nuclear Medicine Communications

Volumn 19, Issue 3, 1998, Pages 263-270

  Ryding, Erik ^a   SjÖHolm, Hans ^a   RoséN, Ingmar ^a   Ohlsson, Tomas ^a   Freccero Rosman, Konrad ^a   Levander, Sten ^a   Tuninger, Eva ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 5,6 DIMETHOXYSALICYLAMIDE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BASAL GANGLION; CEREBELLUM; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; FRONTAL CORTEX; HUMAN; MALE; RADIATION DOSE; RECEPTOR AFFINITY; RECEPTOR DENSITY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031971457     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199803000-00011     Document Type: Article

References (12)

1. Bloom FE. Advancing a neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 1993; 50: 224-227.
2. Mackay AV, Iversen LL, Rossor M et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 1982; 39: 991-997.
3. Joyce JN, Lexow N, Bird E, Winokur A. Organization of dopamine D1 and D2-receptors in human striatum: Receptor autoradiographic studies in Huntington’s disease and schizophrenia. Synapse 1988; 2: 546-557.
4. Wong DF, Wagner HN, Jr, Tune LE et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics [published erratum appears in Science 1987; 235: 6231]. Science 1986; 234: 1558-1563.
5. Farde L, Wiesel FA, Stone Elander S et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients: A positron emission tomography study with [HC]raclopride. Arch Gen Psychiatry 1990; 47: 213-219.
6. Hietala J, Syvalahti E, Vuorio K et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994; 51: 116-123.
7. Volk S, Maul F, Htir G et al. Dopamine D2 receptor occupancy measured by SPECT with I-123-iodobenzamine in chronic schizophrenia. Psychiatry Research: Neuroimaging 1994; 55: 111-118.
8. Hall H, Hcigberg T, Halldin C et al. NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors. Psychophannacology Berlin 1991; 103:6-18.
9. Hcigberg T, Striim P, Hall H et al. Syntheses of [l21I]-, [l2r, I[-and unlabelled (S)-3-iodo-5,6-dimethoxyl-N-[(l-ethyI-2-pyrrolidinyDmethyl [salicylamide (NCQ298), selective ligands for the study of dopamine D2-receptors. Acta Phar-machol Nordica 1990; 2: 53-60.
10. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. ICRP 30, Vol. 1. New York: Pergamon Press, 1978.
11. Kretschmann HJ, Weirinch W. Neuroanatomy and cranial computed tomography. Stuttgart: Thieme Verlag, 1986.
12. Schwartz J-C, Levesque D, Martes M-P, Sokoloff P. Dopamine D3 receptor: Basic and clinical aspects. Clin Neuro-pharmacol 1993; 16: 295-314.